Transarterial chemoembolization (TACE) is a well-established treatment for hepatocellular
carcinoma (HCC). TACE has a clearly delineated role within the Barcelona Clinic Liver
Cancer (BCLC) staging framework, and TACE has been shown to bridge patients to transplantation
and to downsize patients' tumor burden to meet transplantation criteria. Radioembolization
(RE) also has an evolving role in the treatment of HCC. RE has evidence-based applications
across the range of BCLC stages ranging from segmentectomy for patients with solitary
lesions not amenable to ablation to lobar therapy for patients with multifocal HCC,
and to treatment of advanced disease with portal vein thrombosis. This article aims
to elucidate the evidence behind these therapies and to provide a rationale for their
utilization across the spectrum of BCLC stages in the treatment of HCC.
Keywords
interventional oncology - transarterial chemoembolization - radioembolization
